| Summary: | Background: It is currently recommended to vaccinate against SARS CoV-2 for people with
multiple sclerosis (MS), but it is uncertain what effect it will have on people with MS (PwMS).
Objectives: We aimed to compare the side effects of the first and second doses of the
Sinopharm vaccine in PwMS.
Materials & Methods: This descriptive-analytical follow-up study was conducted on
PwMS patients in Kermanshah province, Iran, who received the Sinopharm vaccine using
the nationwide MS registry of Iran (NMSRI) by available methods between May and August
2021. Using a researcher-made questionnaire, demographic and clinical information about
PwMS, as well as side effects from the Sinopharm vaccine were collected by telephone 5-14
days after the first and second doses. Data were analyzed using SPSS software version 25.
Results: Study participants included 188 PwMS, including 148 females (78.7%) and 40
males (21.3%). PwMS had Median age of 42.66±11.1 years and Median 9.57±7.0 for
disease duration. In the 1st dose, the prevalence of side effects was significantly higher
than in the second dose (58.5% vs 47.0%, P=0.012). Fatigue (30.1%), myalgia (29.8%),
fever (25.0%), and headache (22.3%) were the most common in the first dose, and fatigue
(27.1%), headache (18.6%), myalgia (17.5%) and fever (14.9%) were the most common in
the second dose. COVID-19 was present in 51 people (27.3%) before vaccination.
Conclusion: Sinopharm vaccine side effects were significantly more prevalent in the first
dose than in the second dose. Most side effects are moderate in severity and transient.
|
|---|